The EU is challenged by a persistent leadership gap in the global health innovation landscape, with the US leading in corporate health innovation and venture capital (VC) funding. The EU health innovation landscape is more concentrated in older "incumbent leading firms," while the US has a more...

This paper provides empirical evidence on which M&A deals spur innovation, and which stifle it. To do so, we consider not only the product market position of the acquiring firm, but also the position of both target and acquirer in the technology space. Focusing on the antidiabetic drugs market,...

The EU is challenged by a persistent leadership gap in the global health innovation landscape, with the US leading in corporate health innovation and venture capital (VC) funding. The EU health innovation landscape is more concentrated in older "incumbent leading firms," while the US has a more...

This paper analyzes M&A patterns of R&D projects in the antidiabetics industry. For this purpose, we construct a database with all corporate individual antidiabetics R&D projects over the period 1997 - 2017, and add detailed information on firms' technology dimension using patent information,...

Da der Pharmasektor eine der forschungsintensivsten Branchen weltweit ist, können Übernahmen erhebliche negative wie positive Auswirkungen auf Innovationen haben. In diesem Wochenbericht werden auf Basis von internationalen Unternehmensdaten der Jahre 1997 bis 2017 Übernahmen in der...

The competitiveness of countries and that of firms are different concepts. EU GDP is stable at two-thirds of the US, but productivity growth has lagged since the 1990s. The EU does better on wealth equality and clean-tech export shares. The EU faces two supply-side disadvantages: high energy...